An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
NCT00675844 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2023-08-14
Summary
Extension study for participants currently participating in Protocols ACH443-015 and ACH443-018.
Conditions
- HIV Infections
Interventions
- DRUG
-
Elvucitabine
10 milligrams (mg) elvucitabine daily as part of an ART regimen
Sponsors & Collaborators
-
Achillion, a wholly owned subsidiary of Alexion
collaborator INDUSTRY -
Alexion Pharmaceuticals, Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-05-31
- Primary Completion
- 2010-03-31
- Completion
- 2010-03-31
Countries
- United States
Study Locations
More Related Trials
-
Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.
NCT00386659 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy
NCT01338025 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05917509 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY
NCT06823596 ·Status: RECRUITING ·Phase: NA
-
A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1
NCT00824369 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
NCT06749054 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
NCT01286740 ·Status: COMPLETED ·Phase: PHASE2
-
Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy
NCT00001899 ·Status: COMPLETED
-
An Extension of Protocol PRO 140_CD01 Study
NCT02355184 ·Status: TERMINATED ·Phase: PHASE2
-
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
NCT00532168 ·Status: COMPLETED ·Phase: PHASE4
-
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
NCT00734344 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805 ·Status: RECRUITING ·Phase: PHASE3
-
A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen
NCT00749580 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
NCT01967940 ·Status: COMPLETED ·Phase: PHASE3
-
A Long-term Follow-up of the HIV-NAT Cohort
NCT00411983 ·Status: RECRUITING
-
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
NCT01533259 ·Status: COMPLETED ·Phase: PHASE3
-
Advanced HIV: Outcomes for Rapid ART
NCT05526118 ·Status: UNKNOWN
-
Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection
NCT02176135 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART
NCT01571466 ·Status: COMPLETED ·Phase: PHASE1
-
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
NCT06203132 ·Status: RECRUITING ·Phase: PHASE3
-
Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
NCT00562510 ·Status: TERMINATED ·Phase: PHASE3
-
Effects of Intensive cART During Acute/Early HIV Infection
NCT01154673 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV
NCT03101592 ·Status: TERMINATED ·Phase: NA
-
MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection
NCT00614458 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients
NCT00504452 ·Status: TERMINATED ·Phase: PHASE2